Pharmafile Logo
Pharmafocus logo
Advanced Search

Lupus

Showing 9 posts of 24 posts found.

GSK

NICE says no to lupus treatment

September 30, 2011
Sales and Marketing Benylsta, GSK, Lupus, NICE

NICE has rejected GSK’s new lupus treatment Benlysta in draft guidance.Co-developed with biotech company HGS, the drug has been hailed …

News

European recommendation for GSK’s lupus drug Benlysta

May 23, 2011
Sales and Marketing Benlysta, CHMP, GlaxoSmithKline, Lupus

GlaxoSmithKline’s first-in-class lupus drug Benlysta has been given a major boost by regulators in the European Union. The European Medicines …

News
systemic lupus erythematosus (SLE)

US approval for GSK’s lupus treatment Benlysta

March 10, 2011
Sales and Marketing Benlysta, GSK, GlaxoSmithKline, Human Genome Sciences, Lupus, belimumab, systemic lupus erythematosus

GlaxoSmithKline’s lupus treatment Benylsta has won an historic approval in the US, but will have to prove its safety record …

News
systemic lupus erythematosus

UCB lupus candidate shows disease benefits

November 11, 2010
Benlysta, Lupus, UCB, epratuzumab, monoclonal antibody, systemic lupus erythematosus

A new monoclonal antibody targeting the autoimmune disease lupus is continuing to show a positive effect on sufferers, its manufacturer …

News

Benlysta to be fast-tracked by FDA

August 20, 2010
Sales and Marketing Benlysta, GSK, HGS, Lupus

 New lupus drug Benlysta has been given priority review status by the FDA.Benlysta (belimumab) has been developed by Human Genome …

News

UCB’s new lupus treatment promising

June 17, 2010
Research and Development Benlysta, Lupus, UCB, epratuzumab

A new monoclonal antibody treatment for lupus has shown promise in phase II trials, according to UCB. The biopharmaceutical company …

News

EU regulators to assess potential lupus breakthrough drug

June 8, 2010
Sales and Marketing Benlysta, Human Genome Sciences, Lupus

GlaxoSmithKline and Human Genome Sciences have submitted a marketing application to the European Medicines Agency for their new lupus drug. …

News

Secondary endpoints failure take shine off Benlysta

April 21, 2010
Sales and Marketing GSK, HGS, Lupus

GlaxoSmithKline’s lupus treatment has failed to reach a statistically significant secondary endpoint in the second of two phase III trials. …

News

Lupus drug shows surprise phase III success

July 23, 2009
Research and Development, Sales and Marketing Benlysta, GSK, HGS, Lupus

 GSK and Human Genome Sciences’ lupus drug Benlysta has surprised analysts by showing unexpectedly positive results in a pivotal late-stage …

News
The Gateway to Local Adoption Series

Latest content

Five Facts about the menopause

March 6, 2026

Zello Appoints Kevin Bailey as Group Chief Medical Officer

March 6, 2026

BioDuro establishes joint manufacturing venture with Cenra

March 6, 2026

Symbiosis appoints Joanne Anderson as Chief Commercial Officer

March 6, 2026

Secarna Pharmaceuticals and Curie.Bio expand existing partnership

March 6, 2026